The preclinical discovery and development of paliperidone for the treatment of schizophrenia

References

• Product information Invega® (paliperidone). Initial US approval: 2006. Reference ID: 4119109 - FDA.
   Google Scholar
• Chue PS, MacKenzie EM, Chue JA, et al. The pharmacology and formulation of paliperidone extended release. Expert Rev Neurother. 2012;12:1399–1410.
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics Invega® (paliperidone).
   Google Scholar
• Jarema M, Bieńkowski P, Heitzman J, et al. Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia. Psychiatr Pol. 2017;51:7–21.
   PubMed Web of Science ®Google Scholar
• Bishara D. Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2010;6:561–572.
   PubMed Web of Science ®Google Scholar
• Corena-McLeod M. Comparative pharmacology of risperidone and paliperidone. Drugs R D. 2015;15:163–174.
   PubMed Web of Science ®Google Scholar
• Aravagiri M, Marder SR. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology (Berl). 2002;159:424–431.
   PubMed Web of Science ®Google Scholar
• Aravagiri M, Yuwiler A, Marder SR. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology (Berl). 1998;139:356–363.
   PubMed Web of Science ®Google Scholar
• Aquilante CL, Letrent SP, Pollack GM, et al. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci. 2000;66:47–51.
   Web of Science ®Google Scholar
• Wang JS, Ruan Y, Taylor RM, et al. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol. 2004;7:415–419.
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Wang JS, Markowitz JS, et al. Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacology. 2007;32:757–764.
   PubMed Web of Science ®Google Scholar
• van Beijsterveldt LE, Geerts RJ, Leysen JE, et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl). 1994;114:53–62.
   PubMed Web of Science ®Google Scholar
• Mannens G, Meuldermans W, Snoeck E, et al. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl). 1994;114:566–572.
   PubMed Web of Science ®Google Scholar
• Cleton A, Rossenu S, Vermeulen A, et al. A pharmacokinetic model to document the interconversion between paliperidone’s enantiomers. Clin Pharmacol Ther. 2006;79:P55.
   Web of Science ®Google Scholar
• Paliperidone, Product Monograph, PrMylan-paliperidone. Toronto, Canada. 13 December 2017, Revised 2019 Jun 15.
   Google Scholar
• Meuldermans W, Hendrickx J, Mannens G, et al. The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab Dispos. 1994;22:129–138.
   PubMed Web of Science ®Google Scholar
• Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36:769–779.
   PubMed Web of Science ®Google Scholar
• Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124:57–73.
   PubMed Web of Science ®Google Scholar
• Leysen JE, Janssen PMF, Megens AAHP, et al. Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994;55:5–12.
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29–39.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13:27–35.
   PubMed Web of Science ®Google Scholar
• Knight JA, Smith C, Toohey N, et al. Pharmacological analysis of the novel, rapid, and potent inactivation of the humn 5-hydroxytryptamine7 receptor by risperidone, 9-OH-risperidone, and other inactivating antagonists. Mol Pharmacol. 2009;75:374–380.
   PubMed Web of Science ®Google Scholar
• Kantrowitz J, Citrome L. Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evid. 2007;2:261–271.
   Google Scholar
• Clarke WP, Chavera TA, Silva M, et al. Signalling profile differences: paliperidone versus risperidone. Br J Pharmacol. 2013;170:532–545.
   PubMed Web of Science ®Google Scholar
• Heusler P, Newman-Tancredi A, Castro-Fernandez A, et al. Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. Neuropharmacology. 2007;52:1106–1113.
   PubMed Web of Science ®Google Scholar
• Fornito A, Yücel M, Patti J, et al. Mapping grey matter reductions in schizophrenia: an anatomical likelihood estimation analysis of voxel-based morphometry studies. Schizophr Res. 2009;108:104–113.
   PubMed Web of Science ®Google Scholar
• Henn FA, Vollmayr B. Neurogenesis: what is its role in the cause and cure of depression? Drug Discov Today. 2006;3:503–506.
   Google Scholar
• Kumari V. Do psychotherapies produce neurobiological effects? Acta Neuropsychiatr. 2006;18:61–70.
   PubMed Web of Science ®Google Scholar
• Angelucci F, Mathe AA, Aloe L. Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Prog Brain Res. 2004;146:151–165.
   PubMed Web of Science ®Google Scholar
• Buckley PF, Mahadik S, Pillai A, et al. Neurotrophins and schizophrenia. Schizophr Res. 2007;94:1–11.
   PubMed Web of Science ®Google Scholar
• Green W, Patil P, Marsden CA, et al. Treatment with olanzapine increases cell proliferation in the subventricular zone and prefrontal cortex. Brain Res. 2006;1070:242–245.
   PubMed Web of Science ®Google Scholar
• Halim ND, Weickert CS, McClintock BW, et al. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology. 2004;29:1063–1069.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Hopkins T, Pixley SK. Differential effects of antipsychotic and antidepressant drugs on neurogenic regions in rats. Brain Res. 2010;1354:23–29.
   PubMed Web of Science ®Google Scholar
• Wakade CG, Mahadik SP, Waller JL, et al. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res. 2002;69:72–79.
   PubMed Web of Science ®Google Scholar
• Gassó P, Mas S, Molina O, et al. Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;36:71–77.
   PubMed Web of Science ®Google Scholar
• Gumuslu E, Mutlu O, Kokturk S, et al. Effects of asenapine and paliperidone on depression, anxiety and analgesy in mice: alterations in brain neurotrophic factors, neurogenesis, and blood enzyme levels. Chin J Physiol. 2018;61:280–292.
   PubMed Web of Science ®Google Scholar
• Hanson ND, Nemeroff CB, Owens MJ. Lithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus. J Pharmacol Exp Ther. 2011;337:180–186.
   PubMed Web of Science ®Google Scholar
• Chlan-Fourney J, Ashe P, Nylen K, et al. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res. 2002;954:11–20.
   PubMed Web of Science ®Google Scholar
• Angelucci F, Mathé AA, Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res. 2000;60:783–794.
   PubMed Web of Science ®Google Scholar
• Pillai A, Terry AV, Mahadik SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res. 2006;82:95–106.
   PubMed Web of Science ®Google Scholar
• Del Pilar Corena-McLeod M, Oliveros A, Charlesworth C, et al. Paliperidone as a mood stabilizer: a pre-frontal cortex synaptosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression. Brain Res. 2008;1233:8–19.
   PubMed Web of Science ®Google Scholar
• Gorron NL, Corena-McLeod M, Richelson E In-silico homology prediction, post-translational modifications and effects on tertiary structure of human proteins affected by mood stabilizers treatment based on rat synaptoneurosomal preparations from the pre-frontal cortex: an inexpensive approach for drug target discovery and validation. Proceedings of the 49th National Meeting of the American College of Neuropsychopharmacology, Miami Beach, Florida. 2010;5–9
   Google Scholar
• Corena-McLeod M, Gordillo A, Oliveros A, et al. Dfferential protein expression of risperidone and paliperidone in rat pre-frontal cortex: a dose response comparison. Biol Psychiatry. 2010;67:1S–271S.
   PubMed Web of Science ®Google Scholar
• Corena-McLeod M, Walss-Bass C, Oliveros A, et al. New model of action for mood stabilizers: phosphoproteome from rat pre-frontal cortex synaptoneurosomal preparations. PlosOne. 2013;8:e52147.
   PubMed Web of Science ®Google Scholar
• Dremencov E, El Mansari M, Blier P. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology (Berl). 2007;194:63–72.
   PubMed Web of Science ®Google Scholar
• Dremencov E, El Mansari M, Blier P. Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry. 2007;61:671–678.
   PubMed Web of Science ®Google Scholar
• Dong H, Wang Q, Zhu D, et al. Paliperidone increases spontaneous and evoked firing of mesocortical dopaminergic neurons by activating a hyperpolarization-activated inward current. Schizophr Res. 2016;176:252–258.
   PubMed Web of Science ®Google Scholar
• Peng L, Zhu D, Feng X, et al. Paliperidone protects prefrontal cortical neurons from damages caused by MK-801 via Akt1/GSK3β signaling pathway. Schizophr Res. 2013;147:14–23.
   PubMed Web of Science ®Google Scholar
• Lin CH, Yeh SH, Lin CH, et al. A role for the PI-3 kinase signaling pathway in fear conditioning and synaptic plasticity in the amygdala. Neuron. 2001;31:841–851.
   PubMed Web of Science ®Google Scholar
• Emamian ES. AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci. 2012;5:1–12.
   PubMed Web of Science ®Google Scholar
• Kozlovsky N, Shanon-Weickert C, Tomaskovic-Crook E, et al. Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. J Neural Transm. 2004;111:1583–1592.
   PubMed Web of Science ®Google Scholar
• Nadri C, Dean B, Scarr E, et al. GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Schizophr Res. 2004;71:377–382.
   PubMed Web of Science ®Google Scholar
• Patel RB, Patel MR, Bhatt KK, et al. Risperidone microemulsion for transnasal delivery: pharmacodynamic and pharmacokinetic evaluation. Pharm Nanotechnol. 2013;1:44–53.
   Google Scholar
• Patel MR, Patel RB, Bhatt KK, et al. Paliperidone microemulsion for nose-to-brain targeted drug delivery system: pharmacodynamic and pharmacokinetic evaluation. Drug Deliv. 2016;23:346–354.
   PubMed Web of Science ®Google Scholar
• Castagné V, Moser PC, Porsolt RD. Preclinical behavioral models for predicting antipsychotic activity. Adv Pharmacol. 2009;57:381–418.
   PubMedGoogle Scholar
• Chartoff EH, Heusner CL, Palmiter RD. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology. 2005;30:1324–1333.
   PubMed Web of Science ®Google Scholar
• Sun F, Su Z, Sui C, et al. Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives - Comparison to paliperidone and risperidone in mice and rats. Basic Clin Pharmacol Toxicol. 2010;107:656–662.
   PubMed Web of Science ®Google Scholar
• Marchese G, Pittau B, Casu G, et al. A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats. Eur Psychiatry. 2010;25:92–100.
   PubMed Web of Science ®Google Scholar
• Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62:1363–1370.
   PubMed Web of Science ®Google Scholar
• Ozawa K, Hashimoto K, Kishimoto T, et al. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: A neurodevelopmental animal model of schizophrenia. Biol Psychiatry. 2006;59:546–554.
   PubMed Web of Science ®Google Scholar
• Richtand NM, Ahlbrand R, Horn P, et al. Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation. J Psychiatr Res. 2011;45:1194–1201.
   PubMed Web of Science ®Google Scholar
• Kumar U, Mohanty B. Atypical antipsychotic paliperidone prevents behavioral deficits in mice prenatally challenged with bacterial endotoxin lipopolysaccharide. Eur J Pharmacol. 2015;747:181–189.
   PubMed Web of Science ®Google Scholar
• Roenker NL, Gudelsky G, Ahlbrand R, et al. Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801. Neurosci Lett. 2011;500:167–171.
   PubMed Web of Science ®Google Scholar
• Carlsson A, Waters N, Waters S, et al. Network interactions in schizophrenia - therapeutic implications. Brain Res Rev. 2000;31:342–349.
   PubMedGoogle Scholar
• MacDowell KS, Munarriz-Cuezva E, Caso JR, et al. Paliperidone reverts Toll-like receptor 3 signaling pathway activation and cognitive deficits in a maternal immune activation mouse model of schizophrenia. Neuropharmacology. 2017;116:196–207.
   PubMed Web of Science ®Google Scholar
• Richtand NM, Taylor B, Welge JA, et al. Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions. Neuropharmacology. 2006;31:77–89.
   Google Scholar
• Abekawa T, Ito K, Koyama T. Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic. Naunyn-Schmiedebergs’ Arch Pharmacol. 2007;375:261–271.
   PubMed Web of Science ®Google Scholar
• López-Gil X, Babot Z, Amargós-Bosch M, et al. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology. 2007;32:2087–2097.
   PubMed Web of Science ®Google Scholar
• Meyer U, Knuesel I, Nyffeler M, et al. Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis. Psychopharmacol (Berl). 2010;208:531e543.
   Web of Science ®Google Scholar
• Khandaker GM. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2:258–270.
   PubMed Web of Science ®Google Scholar
• MacDowell KS, Caso JR, Martín-Hernández D, et al. The atypical antipsychotic paliperidone regulates endogenous antioxidant/anti-inflammatory pathways in rat models of acute and chronic restraint stress. Neurotherapeutics. 2016;13:833–843.
   PubMed Web of Science ®Google Scholar
• Monji A, Kato TA, Mizoguchi Y, et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;42:115–121.
   PubMed Web of Science ®Google Scholar
• Sadowska-Bartosz I, Galiniak S, Bartosz G, et al. Antioxidant properties of atypical antipsychotic drugs used in the treatment of schizophrenia. Schizophr Res. 2016;176:245–251.
   PubMed Web of Science ®Google Scholar
• Gilca M, Piriu G, Gaman L, et al. A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics. Psychopharmacology (Berl). 2014;231:4703–4710.
   PubMed Web of Science ®Google Scholar
• Noto C, Ota VK, Gadelha A, et al. Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone. J Psychiatr Res. 2015;68:210–216.
   PubMed Web of Science ®Google Scholar
• Demirci K, Özçankaya R, Yilmaz HR, et al. Paliperidone regulates intracellular redox system in rat brain: role of purine mechanism. Redox Rep. 2015;20:170–176.
   PubMed Web of Science ®Google Scholar
• Gołembiowska K, Żylewska A. Agonists of A1 and A2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum. Brain Res. 1998;806:202–209.
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Safarcherati A, Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog Neuro-Psychopharmacol Biol Psychiatry. 2005;29:253–259.
   PubMed Web of Science ®Google Scholar
• Reinke A, Martins MR, Lima MS, et al. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett. 2004;372:157–160.
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. Nitric Oxide. 2002;7:297–300.
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Shohami E. Endocannabinoids and traumatic brain injury. Mol Neurobiol. 2007;36:68–74.
   PubMed Web of Science ®Google Scholar
• Kucerova J, Tabiova K, Drago F, et al. Therapeutic potential of cannabinoids in schizophrenia. Recent Pat CNS Drug Discov. 2014;9:13–25.
   PubMedGoogle Scholar
• Eggan SM, Hashimoto T, Lewis DA. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry. 2008;65:772–784.
   PubMed Web of Science ®Google Scholar
• De Marchi N, De Petrocellis L, Orlando P, et al. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2003;2:5.
   PubMedGoogle Scholar
• Ortega-Alvaro A, Aracil-Fernandez A, Garcia-Gutierrez MS, et al. Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology. 2011;36:1489–1504.
   PubMed Web of Science ®Google Scholar
• MacDowell K, Sayd A, García-Bueno B, et al. Effects of the antipsychotic paliperidone on stress-induced changes in the endocannabinoid system in rat prefrontal cortex. World J Biol Psychiatry. 2017;18:457–470.
   PubMed Web of Science ®Google Scholar
• Brzozowska NI, de Tonnerre E, Li KM, et al. The differential binding of antipsychotic drugs to the ABC transporter P-glycoprotein predicts cannabinoid–antipsychotic drug interactions. Neuropsychopharmacology. 2017;42:2222–2231.
   PubMed Web of Science ®Google Scholar
• Eddy NB, Leimbach D. Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther. 1953;107:385–393.
   PubMed Web of Science ®Google Scholar
• Karlsson P, Hargarter L, Dencker E, et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies (PAL-115). Pharmacopsychiatry. 2007;40:A106.
   Web of Science ®Google Scholar
• Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006;163:396–401.
   PubMed Web of Science ®Google Scholar
• Nikiforuk A. Targeting the serotonin 5-HT7 receptor in the search for treatments for CNS disorders: rationale and progress to date. CNS Drugs. 2015;29:265–275.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115:260–267.
   PubMed Web of Science ®Google Scholar
• Krogmann A, Peters L, von Hardenberg L, et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entites. CNS Spectr. 2019;24:41–68.
   Web of Science ®Google Scholar
• Suzuki T, Uchida H, Takeuchi H, et al. A review on schizophrenia and relapse a quest for user-friendly psychopharmacotherapy. Hum Psychopharmacl. 2014;29:414–426.
   PubMed Web of Science ®Google Scholar
• Janicak PG, Winans E. Paliperidone ER:a review of the clinical trial data. Neuropsychiatr Dis Treat. 2007;3:869–897.
   PubMedGoogle Scholar
• Brasso C, Bellino S, Bozzatello P, et al. Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia. Neuropsychiatr Dis Treat. 2017;12:2767–2779.
   Google Scholar
• Emsley R, Parellada E, Bioque M, et al. Real-world data on paliperidone palmitate from the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies. Int Clin Psychopharmacol. 2017;33:15–33.
   Web of Science ®Google Scholar